Research progress in the metabolic reprogramming of hepatocellular carcinoma (Review)
- Authors:
- Wenyue Gao
- Jing Wang
- Yuting Xu
- Hongbo Yu
- Sitong Yi
- Changchuan Bai
- Qingwei Cong
- Ying Zhu
-
Affiliations: Department of Infectious Diseases, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116000, P.R China, Internal Department of Chinese Medicine, Dalian Hospital of Traditional Chinese Medicine, Dalian, Liaoning 116000, P.R China - Published online on: May 24, 2024 https://doi.org/10.3892/mmr.2024.13255
- Article Number: 131
-
Copyright: © Gao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J and Finn RS: Hepatocellular carcinoma. Nat Rev Dis Primers. 7:62021. View Article : Google Scholar : PubMed/NCBI | |
|
Xing Y, Zhao S, Zhou BP and Mi J: Metabolic reprogramming of the tumour microenvironment. FEBS J. 282:3892–3898. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Martínez-Reyes I and Chandel NS: Cancer metabolism: Looking forward. Nat Rev Cancer. 21:669–680. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Ward PS and Thompson CB: Metabolic reprogramming: A cancer hallmark even warburg did not anticipate. Cancer Cell. 21:297–308. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Vander Heiden MG, Cantley LC and Thompson CB: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Warburg O: On the origin of cancer cells. Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI | |
|
Li C, Chen J, Li Y, Wu B, Ye Z, Tian X, Wei Y, Hao Z, Pan Y, Zhou H, et al: 6-Phosphogluconolactonase promotes hepatocellular carcinogenesis by activating pentose phosphate pathway. Front Cell Dev Biol. 9:7531962021. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Lu LL, Wen D, Liu DL, Dong LL, Gao DM, Bian XY, Zhou J, Fan J and Wu WZ: MiR-612 regulates invadopodia of hepatocellular carcinoma by HADHA-mediated lipid reprogramming. J Hematol Oncol. 13:122020. View Article : Google Scholar : PubMed/NCBI | |
|
Vettore L, Westbrook RL and Tennant DA: New aspects of amino acid metabolism in cancer. Br J Cancer. 122:150–156. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhuang X, Chen Y, Wu Z, Xu Q, Chen M, Shao M, Cao X, Zhou Y, Xie M, Shi Y, et al: Mitochondrial miR-181a-5p promotes glucose metabolism reprogramming in liver cancer by regulating the electron transport chain. Carcinogenesis. 41:972–983. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N, Yi P, Tang L, Pan Q, Rao S, et al: The cancer metabolic reprogramming and immune response. Mol Cancer. 20:282021. View Article : Google Scholar : PubMed/NCBI | |
|
Vaupel P, Schmidberger H and Mayer A: The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression. Int J Radiat Biol. 95:912–919. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Enzo E, Santinon G, Pocaterra A, Aragona M, Bresolin S, Forcato M, Grifoni D, Pession A, Zanconato F, Guzzo G, et al: Aerobic glycolysis tunes YAP/TAZ transcriptional activity. EMBO J. 34:1349–1370. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Liao W, Du J, Wang Z, Feng Q, Liao M, Liu H, Yuan K and Zeng Y: The role and mechanism of noncoding RNAs in regulation of metabolic reprogramming in hepatocellular carcinoma. Int J Cancer. 151:337–347. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Eu JQ, Kong LR, Wang L, Lim YC, Goh BC and Wong ALA: Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy. Molecules. 25:48312020. View Article : Google Scholar : PubMed/NCBI | |
|
Amann T, Maegdefrau U, Hartmann A, Agaimy A, Marienhagen J, Weiss TS, Stoeltzing O, Warnecke C, Schölmerich J, Oefner PJ, et al: GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol. 174:1544–1552. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Yao J, Tang S, Shi C, Lin Y, Ge L, Chen Q, Ou B, Liu D, Miao Y, Xie Q, et al: Isoginkgetin, a potential CDK6 inhibitor, suppresses SLC2A1/GLUT1 enhancer activity to induce AMPK-ULK1-mediated cytotoxic autophagy in hepatocellular carcinoma. Autophagy. 19:1221–1238. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Shang R, Pu M, Li Y and Wang D: FOXM1 regulates glycolysis in hepatocellular carcinoma by transactivating glucose transporter 1 expression. Oncol Rep. 37:2261–2269. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang P, Sun J, Sun C, Zhao H, Zhang Y and Chen J: BTF3 promotes proliferation and glycolysis in hepatocellular carcinoma by regulating GLUT1. Cancer Biol Ther. 24:22258842023. View Article : Google Scholar : PubMed/NCBI | |
|
Shang R, Wang M, Dai B, Du J, Wang J, Liu Z, Qu S, Yang X, Liu J, Xia C, et al: Long noncoding RNA SLC2A1-AS1 regulates aerobic glycolysis and progression in hepatocellular carcinoma via inhibiting the STAT3/FOXM1/GLUT1 pathway. Mol Oncol. 14:1381–1396. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Yang H, Zhang MZ, Sun HW, Chai YT, Li X, Jiang Q and Hou J: A Novel Microcrystalline BAY-876 formulation achieves long-acting antitumor activity against aerobic glycolysis and proliferation of hepatocellular carcinoma. Front Oncol. 11:7831942021. View Article : Google Scholar : PubMed/NCBI | |
|
DeWaal D, Nogueira V, Terry AR, Patra KC, Jeon SM, Guzman G, Au J, Long CP, Antoniewicz MR and Hay N: Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin. Nat Commun. 9:4462018. View Article : Google Scholar : PubMed/NCBI | |
|
Garcia SN, Guedes RC and Marques MM: Unlocking the Potential of HK2 in Cancer Metabolism and Therapeutics. Curr Med Chem. 26:7285–7322. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao L, Kang M, Liu X, Wang Z, Wang Y, Chen H, Liu W, Liu S, Li B, Li C, et al: UBR7 inhibits HCC tumorigenesis by targeting Keap1/Nrf2/Bach1/HK2 and glycolysis. J Exp Clin Cancer Res. 41:3302022. View Article : Google Scholar : PubMed/NCBI | |
|
Ding Z, Guo L, Deng Z and Li P: Circ-PRMT5 enhances the proliferation, migration and glycolysis of hepatoma cells by targeting miR-188-5p/HK2 axis. Ann Hepatol. 19:269–279. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Chen J, Sun F, Wang Z, Xu W, Yu Y, Ding F and Shen H: miR-202 functions as a tumor suppressor in hepatocellular carcinoma by targeting HK2. Oncol Lett. 19:2265–2271. 2020.PubMed/NCBI | |
|
Lv B, Zhu W and Feng C: Coptisine Blocks Secretion of Exosomal circCCT3 from cancer-associated fibroblasts to reprogram glucose metabolism in hepatocellular carcinoma. DNA Cell Biol. Oct 2–2020.(Epub ahead of print). View Article : Google Scholar | |
|
Wu Q, Wang SP, Sun XX, Tao YF, Yuan XQ, Chen QM, Dai L, Li CL, Zhang JY and Yang AL: HuaChanSu suppresses tumor growth and interferes with glucose metabolism in hepatocellular carcinoma cells by restraining Hexokinase-2. Int J Biochem Cell Biol. 142:1061232022. View Article : Google Scholar : PubMed/NCBI | |
|
Huang J, Chen F, Zhong Z, Tan HY, Wang N, Liu Y, Fang X, Yang T and Feng Y: Interpreting the pharmacological mechanisms of huachansu capsules on hepatocellular carcinoma through combining network pharmacology and experimental evaluation. Front Pharmacol. 11:4142020. View Article : Google Scholar : PubMed/NCBI | |
|
Laussel C and Léon S: Cellular toxicity of the metabolic inhibitor 2-deoxyglucose and associated resistance mechanisms. Biochem Pharmacol. 182:1142132020. View Article : Google Scholar : PubMed/NCBI | |
|
Ma WK, Voss DM, Scharner J, Costa ASH, Lin KT, Jeon HY, Wilkinson JE, Jackson M, Rigo F, Bennett CF and Krainer AR: ASO-Based PKM splice-switching therapy inhibits hepatocellular carcinoma growth. Cancer Res. 82:900–915. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Israelsen WJ and Vander Heiden MG: Pyruvate kinase: Function, regulation and role in cancer. Semin Cell Dev Biol. 43:43–51. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Chen D, Wang Y, Lu R, Jiang X, Chen X, Meng N, Chen M, Xie S and Yan GR: E3 ligase ZFP91 inhibits Hepatocellular Carcinoma Metabolism Reprogramming by regulating PKM splicing. Theranostics. 10:8558–8572. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Tan HW, Leung CO, Chan KK, Ho DW, Leung MS, Wong CM, Ng IO and Lo RC: Deregulated GATA6 modulates stem cell-like properties and metabolic phenotype in hepatocellular carcinoma. Int J Cancer. 145:1860–1873. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Panda AC: Circular RNAs Act as miRNA Sponges. Adv Exp Med Biol. 1087:67–79. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Li Q, Pan X, Zhu D, Deng Z, Jiang R and Wang X: Circular RNA MAT2B promotes glycolysis and malignancy of hepatocellular carcinoma through the miR-338-3p/PKM2 axis under hypoxic stress. Hepatology. 70:1298–1316. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang M, Zhang H, Hong H and Zhang Z: MiR-374b re-sensitizes hepatocellular carcinoma cells to sorafenib therapy by antagonizing PKM2-mediated glycolysis pathway. Am J Cancer Res. 9:765–778. 2019.PubMed/NCBI | |
|
Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F, Wang Q, Wang S, Rong D, Reiter FP, et al: The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther. 5:872020. View Article : Google Scholar : PubMed/NCBI | |
|
Chen M, Liu H, Li Z, Ming AL and Chen H: Mechanism of PKM2 affecting cancer immunity and metabolism in tumor microenvironment. J Cancer. 12:3566–3574. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Feng Y, Xiong Y, Qiao T, Li X, Jia L and Han Y: Lactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy. Cancer Med. 7:6124–6136. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Malvi P, Rawat V, Gupta R and Wajapeyee N: Transcriptional, chromatin, and metabolic landscapes of LDHA inhibitor-resistant pancreatic ductal adenocarcinoma. Front Oncol. 12:9264372022. View Article : Google Scholar : PubMed/NCBI | |
|
Wang S, Zhou L, Ji N, Sun C, Sun L, Sun J, Du Y, Zhang N, Li Y, Liu W and Lu W: Targeting ACYP1-mediated glycolysis reverses lenvatinib resistance and restricts hepatocellular carcinoma progression. Drug Resist Updat. 69:1009762023. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Zhang P and Deng K: MYC Promotes LDHA Expression through MicroRNA-122-5p to potentiate glycolysis in hepatocellular carcinoma. Anal Cell Pathol (Amst). 2022:14351732022.PubMed/NCBI | |
|
Zhang HF, Wang YC and Han YD: MicroRNA-34a inhibits liver cancer cell growth by reprogramming glucose metabolism. Mol Med Rep. 17:4483–4489. 2018.PubMed/NCBI | |
|
Hua S, Liu C, Liu L and Wu D: miR-142-3p inhibits aerobic glycolysis and cell proliferation in hepatocellular carcinoma via targeting LDHA. Biochem Biophys Res Commun. 496:947–954. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Cai J, Chen Z, Zhang Y, Wang J, Zhang Z, Wu J, Mao J and Zuo X: CircRHBDD1 augments metabolic rewiring and restricts immunotherapy efficacy via m(6)A modification in hepatocellular carcinoma. Mol Ther Oncolytics. 24:755–771. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Luo X, Zheng E, Wei L, Zeng H, Qin H, Zhang X, Liao M, Chen L, Zhao L, Ruan XZ, et al: The fatty acid receptor CD36 promotes HCC progression through activating Src/PI3K/AKT axis-dependent aerobic glycolysis. Cell Death Dis. 12:3282021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao C, Wang B, Liu E and Zhang Z: Loss of PTEN expression is associated with PI3K pathway-dependent metabolic reprogramming in hepatocellular carcinoma. Cell Commun Signal. 18:1312020. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng YL, Li L, Jia YX, Zhang BZ, Li JC, Zhu YH, Li MQ, He JZ, Zeng TT, Ban XJ, et al: LINC01554-Mediated glucose metabolism reprogramming suppresses tumorigenicity in hepatocellular carcinoma via downregulating PKM2 expression and inhibiting Akt/mTOR signaling pathway. Theranostics. 9:796–810. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Hu ZQ, Yu SY, Mao L, Zhou ZJ, Wang PC, Gong Y, Su S, Zhou J, Fan J, et al: CircRPN2 inhibits aerobic glycolysis and metastasis in hepatocellular carcinoma. Cancer Res. 82:1055–1069. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Li X, Zhang Y, Ma W, Fu Q, Liu J, Yin G, Chen P, Dai D, Chen W, Qi L, et al: Enhanced glucose metabolism mediated by CD147 contributes to immunosuppression in hepatocellular carcinoma. Cancer Immunol Immunother. 69:535–548. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lin D and Wu J: Hypoxia inducible factor in hepatocellular carcinoma: A therapeutic target. World J Gastroenterol. 21:12171–12178. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, Wenger RH, Gassmann M, Gearhart JD, Lawler AM, Yu AY and Semenza GL: Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 12:149–162. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Guo W, Qiu Z, Wang Z, Wang Q, Tan N, Chen T, Chen Z, Huang S, Gu J, Li J, et al: MiR-199a-5p is negatively associated with malignancies and regulates glycolysis and lactate production by targeting hexokinase 2 in liver cancer. Hepatology. 62:1132–1144. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Z, Zuo X, Zhang Y, Han G, Zhang L, Wu J and Wang X: MiR-3662 suppresses hepatocellular carcinoma growth through inhibition of HIF-1α-mediated Warburg effect. Cell Death Dis. 9:5492018. View Article : Google Scholar : PubMed/NCBI | |
|
Luo W, Hu H, Chang R, Zhong J, Knabel M, O'Meally R, Cole RN, Pandey A and Semenza GL: Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell. 145:732–744. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Zhang C, Zhao Q, Wei W, Dong Z, Shao L, Li J, Wu W, Zhang H, Huang H, et al: The miR-873/NDFIP1 axis promotes hepatocellular carcinoma growth and metastasis through the AKT/mTOR-mediated Warburg effect. Am J Cancer Res. 9:927–944. 2019.PubMed/NCBI | |
|
Kowalik MA, Columbano A and Perra A: Emerging role of the pentose phosphate pathway in hepatocellular carcinoma. Front Oncol. 7:872017. View Article : Google Scholar : PubMed/NCBI | |
|
Stincone A, Prigione A, Cramer T, Wamelink MM, Campbell K, Cheung E, Olin-Sandoval V, Grüning NM, Krüger A, Tauqeer Alam M, et al: The return of metabolism: biochemistry and physiology of the pentose phosphate pathway. Biol Rev Camb Philos Soc. 90:927–963. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lu M, Lu L, Dong Q, Yu G, Chen J, Qin L, Wang L, Zhu W and Jia H: Elevated G6PD expression contributes to migration and invasion of hepatocellular carcinoma cells by inducing epithelial-mesenchymal transition. Acta Biochim Biophys Sin (Shanghai). 50:370–380. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Barajas JM, Reyes R, Guerrero MJ, Jacob ST, Motiwala T and Ghoshal K: The role of miR-122 in the dysregulation of glucose-6-phosphate dehydrogenase (G6PD) expression in hepatocellular cancer. Sci Rep. 8:91052018. View Article : Google Scholar : PubMed/NCBI | |
|
Qin Z, Xiang C, Zhong F, Liu Y, Dong Q, Li K, Shi W, Ding C, Qin L and He F: Transketolase (TKT) activity and nuclear localization promote hepatocellular carcinoma in a metabolic and a non-metabolic manner. J Exp Clin Cancer Res. 38:1542019. View Article : Google Scholar : PubMed/NCBI | |
|
Jia D, Liu C, Zhu Z, Cao Y, Wen W, Hong Z, Liu Y, Liu E, Chen L, Chen C, et al: Novel transketolase inhibitor oroxylin A suppresses the non-oxidative pentose phosphate pathway and hepatocellular carcinoma tumour growth in mice and patient-derived organoids. Clin Transl Med. 12:e10952022. View Article : Google Scholar : PubMed/NCBI | |
|
Luo X, Cheng C, Tan Z, Li N, Tang M, Yang L and Cao Y: Emerging roles of lipid metabolism in cancer metastasis. Mol Cancer. 16:762017. View Article : Google Scholar : PubMed/NCBI | |
|
Shimano H and Sato R: SREBP-regulated lipid metabolism: Convergent physiology-divergent pathophysiology. Nat Rev Endocrinol. 13:710–730. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Muku GE, Blazanin N, Dong F, Smith PB, Thiboutot D, Gowda K, Amin S, Murray IA and Perdew GH: Selective Ah Receptor Ligands Mediate Enhanced SREBP1 Proteolysis to Restrict Lipogenesis in Sebocytes. Toxicol Sci. 171:146–158. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Li H, Chen Z, Zhang Y, Yuan P, Liu J, Ding L and Ye Q: MiR-4310 regulates hepatocellular carcinoma growth and metastasis through lipid synthesis. Cancer Lett. 519:161–171. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Chen J, Ding C, Chen Y, Hu W, Yu C, Peng C, Feng X, Cheng Q, Wu W, Lu Y, et al: ACSL4 reprograms fatty acid metabolism in hepatocellular carcinoma via c-Myc/SREBP1 pathway. Cancer Lett. 502:154–165. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Sun L, Guo H, Zhou S, Wang C, Ji C, Meng F, Liang S, Zhang B, Yuan Y, et al: Targeting SLP2-mediated lipid metabolism reprograming restricts proliferation and metastasis of hepatocellular carcinoma and promotes sensitivity to Lenvatinib. Oncogene. 42:374–388. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Chan DC: Mitochondrial dynamics and its involvement in disease. Annu Rev Pathol. 15:235–259. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wu D, Yang Y, Hou Y, Zhao Z, Liang N, Yuan P, Yang T, Xing J and Li J: Increased mitochondrial fission drives the reprogramming of fatty acid metabolism in hepatocellular carcinoma cells through suppression of Sirtuin 1. Cancer Commun (Lond). 42:37–55. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Li Q, Yao H, Wang Y, Wu Y, Thorne RF, Zhu Y, Wu M and Liu L: circPRKAA1 activates a Ku80/Ku70/SREBP-1 axis driving de novo fatty acid synthesis in cancer cells. Cell Rep. 41:1117072022. View Article : Google Scholar : PubMed/NCBI | |
|
Mok EHK, Leung CON, Zhou L, Lei MML, Leung HW, Tong M, Wong TL, Lau EYT, Ng IOL, Ding J, et al: Caspase-3-Induced Activation of SREBP2 Drives drug resistance via promotion of cholesterol biosynthesis in hepatocellular carcinoma. Cancer Res. 82:3102–3115. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Svensson RU, Parker SJ, Eichner LJ, Kolar MJ, Wallace M, Brun SN, Lombardo PS, Van Nostrand JL, Hutchins A, Vera L, et al: Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models. Nat Med. 22:1108–1119. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zaytseva YY, Rychahou PG, Le AT, Scott TL, Flight RM, Kim JT, Harris J, Liu J, Wang C, Morris AJ, et al: Preclinical evaluation of novel fatty acid synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft model of colorectal cancer. Oncotarget. 9:24787–24800. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Peck B, Schug ZT, Zhang Q, Dankworth B, Jones DT, Smethurst E, Patel R, Mason S, Jiang M, Saunders R, et al: Inhibition of fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised environments. Cancer Metab. 4:62016. View Article : Google Scholar : PubMed/NCBI | |
|
Stine ZE, Schug ZT, Salvino JM and Dang CV: Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discov. 21:141–162. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng C, Geng F, Cheng X and Guo D: Lipid metabolism reprogramming and its potential targets in cancer. Cancer Commun (Lond). 38:272018.PubMed/NCBI | |
|
Li B, Cao Y, Meng G, Qian L, Xu T, Yan C, Luo O, Wang S, Wei J, Ding Y and Yu D: Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway. EBioMedicine. 39:239–254. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Altman BJ, Stine ZE and Dang CV: From Krebs to clinic: Glutamine metabolism to cancer therapy. Nat Rev Cancer. 16:619–634. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Marsico M, Santarsiero A, Pappalardo I, Convertini P, Chiummiento L, Sardone A, Di Noia MA, Infantino V and Todisco S: Mitochondria-Mediated Apoptosis of HCC cells triggered by knockdown of glutamate dehydrogenase 1: Perspective for its inhibition through quercetin and permethylated anigopreissin A. Biomedicines. 9:16642021. View Article : Google Scholar : PubMed/NCBI | |
|
Dai W, Xu L, Yu X, Zhang G, Guo H, Liu H, Song G, Weng S, Dong L, Zhu J, et al: OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism. J Hepatol. 72:909–923. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Xu K, Ding J, Zhou L, Li D, Luo J, Wang W, Shang M, Lin B, Zhou L and Zheng S: SMYD2 promotes hepatocellular carcinoma progression by reprogramming glutamine metabolism via c-Myc/GLS1 Axis. Cells. 12:252022. View Article : Google Scholar : PubMed/NCBI | |
|
Meric-Bernstam F, Tannir NM, Iliopoulos O, Lee RJ, Telli ML, Fan AC, DeMichele A, Haas NB, Patel MR, Harding JJ, et al: Telaglenastat plus cabozantinib or everolimus for advanced or metastatic renal cell carcinoma: An open-label phase I trial. Clin Cancer Res. 28:1540–1548. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Li C, Gui G, Zhang L, Qin A, Zhou C and Zha X: Overview of methionine adenosyltransferase 2A (MAT2A) as an anticancer target: Structure, function, and inhibitors. J Med Chem. 65:9531–9547. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Hung MH, Lee JS, Ma C, Diggs LP, Heinrich S, Chang CW, Ma L, Forgues M, Budhu A, Chaisaingmongkol J, et al: Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinoma. Nat Commun. 12:14552021. View Article : Google Scholar : PubMed/NCBI | |
|
Simile MM, Peitta G, Tomasi ML, Brozzetti S, Feo CF, Porcu A, Cigliano A, Calvisi DF, Feo F and Pascale RM: MicroRNA-203 impacts on the growth, aggressiveness and prognosis of hepatocellular carcinoma by targeting MAT2A and MAT2B genes. Oncotarget. 10:2835–2854. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Li JT, Yang H, Lei MZ, Zhu WP, Su Y, Li KY, Zhu WY, Wang J, Zhang L, Qu J, et al: Dietary folate drives methionine metabolism to promote cancer development by stabilizing MAT IIA. Signal Transduct Target Ther. 7:1922022. View Article : Google Scholar : PubMed/NCBI | |
|
Chaturvedi S, Hoffman RM and Bertino JR: Exploiting methionine restriction for cancer treatment. Biochem Pharmacol. 154:170–173. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kawaguchi K, Han Q, Li S, Tan Y, Igarashi K, Miyake K, Kiyuna T, Miyake M, Chemielwski B, Nelson SD, et al: Intra-tumor L-methionine level highly correlates with tumor size in both pancreatic cancer and melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse models. Oncotarget. 9:11119–11125. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Yip LY, Lee JHJ, Wu Z, Chew HY, Chong PKW, Teo CC, Ang HY, Peh KLE, Yuan J, et al: Methionine is a metabolic dependency of tumor-initiating cells. Nat Med. 25:825–837. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Yang C, Zhang H, Zhang L, Zhu AX, Bernards R, Qin W and Wang C: Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 20:203–222. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Todisco S, Convertini P, Iacobazzi V and Infantino V: TCA cycle rewiring as emerging metabolic signature of hepatocellular carcinoma. Cancers (Basel). 12:682019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang H, Zhou Y, Xu H, Wang X, Zhang Y, Shang R, O'Farrell M, Roessler S, Sticht C, Stahl A, et al: Therapeutic efficacy of FASN inhibition in preclinical models of HCC. Hepatology. 76:951–966. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Jin H, Wang S, Zaal EA, Wang C, Wu H, Bosma A, Jochems F, Isima N, Jin G, Lieftink C, et al: A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer. Elife. 9:e567492020. View Article : Google Scholar : PubMed/NCBI | |
|
Hay N: Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy? Nat Rev Cancer. 16:635–649. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, Dipaola RS, Stein MN, Rocha Lima CM, Schlesselman JJ, Tolba K, Langmuir VK, et al: A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 71:523–530. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Reyes R, Wani NA, Ghoshal K, Jacob ST and Motiwala T: Sorafenib and 2-Deoxyglucose synergistically inhibit proliferation of both sorafenib-sensitive and -resistant HCC cells by inhibiting ATP production. Gene Expr. 17:129–140. 2017. View Article : Google Scholar : PubMed/NCBI |
